You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ER-Positive, HER2- Negative Breast Cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer, Cancer of the Breast Trial in Saint Louis (VENTANA MIB-1 Ki67 assay, Oncotype DX® Recurrence Score, PAM50-based

Not yet recruiting
  • Breast Cancer
  • Cancer of the Breast
  • VENTANA MIB-1 Ki67 assay
  • +4 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Apr 18, 2023

Breast Cancer Trial (Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression)

Not yet recruiting
  • Breast Cancer
  • Ovarian Function Suppression + Aromatase Inhibitor
  • Adjuvant Chemotherapy + Ovarian Function Suppression
  • (no location specified)
May 19, 2023

Breast Tumors Trial in Shanghai (Epirubicin, Docetaxel, cyclophosphamide)

Completed
  • Breast Neoplasms
  • Shanghai, Shanghai, China
    Ruijin Hospital
Oct 26, 2022

ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer, a Germline or Somatic BRCA Mutation, or a

Recruiting
  • ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer
  • a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
  • Montpellier, France
  • +1 more
Nov 16, 2022

Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)

Recruiting
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jun 12, 2023

Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv Trial in Chicago

Not yet recruiting
  • Estrogen-receptor-positive Breast Cancer
  • +3 more
  • elacestrant, palbociclib, abemaciclib, ribociclib
  • Chicago, Illinois
    Northwestern University
Sep 25, 2023

Gut and Tumor Microbiome in Advanced ER-positive and

Not yet recruiting
  • Breast Cancer
  • Melanoma
  • Observation
  • (no location specified)
Nov 6, 2023

ER+, HER2- Advanced Breast Cancer, Metastatic Breast Cancer Trial in Luoyang, Shanghai (TFX06 tablet)

Recruiting
  • ER+, HER2- Advanced Breast Cancer
  • Metastatic Breast Cancer
  • TFX06 tablet
  • Luoyang, Henan, China
  • +1 more
Jun 25, 2023

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Trial (Giredestrant, Fulvestrant, Abemaciclib)

Not yet recruiting
  • Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
  • (no location specified)
Sep 26, 2023

Breast Cancer Trial (Giredestrant, Giredestrant plus triptorelin, Anastrozole plus triptorelin)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Jun 13, 2023

ER+ Breast Cancer, HER2-negative Breast Cancer Trial in Christchurch, London, Oxford (Palbociclib 125Mg Tab, Fulvestrant

Recruiting
  • ER+ Breast Cancer
  • HER2-negative Breast Cancer
  • Palbociclib 125Mg Tab
  • +5 more
  • Christchurch, United Kingdom
  • +3 more
May 19, 2022

ER+ HER2- Advanced Breast Cancer Trial in Chuo-ku, Kashiwa, Koto-ku (AZD9833)

Active, not recruiting
  • ER+ HER2- Advanced Breast Cancer
  • Chuo-ku, Japan
  • +2 more
Jan 24, 2023

Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer Trial (OP-1250, Fulvestrant, Anastrozole)

Not yet recruiting
  • Breast Cancer
  • +4 more
  • (no location specified)
Aug 31, 2023

Triple Negative Breast Cancer, HER2-negative Breast Cancer Trial in Tampa (HER2 - primed Dendritic cells, HER3 - primed

Recruiting
  • Triple Negative Breast Cancer
  • HER2-negative Breast Cancer
  • HER2 - primed Dendritic cells
  • HER3 - primed Dendritic cells
  • Tampa, Florida
    Moffitt Cancer Center
Jan 10, 2023

TNBC - Triple-Negative Breast Cancer Trial (Alkaline Glucosodiene Molecules)

Not yet recruiting
  • TNBC - Triple-Negative Breast Cancer
  • Alkaline Glucosodiene Molecules
  • (no location specified)
Jul 14, 2023

Older Women With ER Positive, HER2 Negative Early Breast Cancer

Enrolling by invitation
  • Breast Cancer Female
  • Translational study
  • Sutton, United Kingdom
    The Royal Marsden NHS Foundation Trust
Feb 8, 2023

Metastatic Breast Cancer Trial in Chuo-ku, Nihonbashi, Koami-cho (Paclitaxel, Bevacizumab, Letrozole)

Completed
  • Metastatic Breast Cancer
  • Chuo-ku, Nihonbashi, Koami-cho, Tokyo, Japan
    Japan Breast Cancer Research Group
Aug 2, 2022

Breast Tumors Trial in Chuo Ku, Koto-Ku (H3B-6545, Antihistamine)

Active, not recruiting
  • Breast Neoplasms
  • Chuo Ku, Japan
  • +1 more
Dec 19, 2022

Advanced or Metastatic Breast Cancer Trial in Paris (Milademetan, Patient Reported Outcomes (PROs) and Health-Related Quality of

Not yet recruiting
  • Advanced or Metastatic Breast Cancer
  • Milademetan
  • Patient Reported Outcomes (PROs) and Health-Related Quality of Life (HRQOL)
  • Paris, France
    Institut Curie
Jun 27, 2023

Breast Cancer Trial in Sarasota, Nashville (AC699)

Recruiting
  • Breast Cancer
  • Sarasota, Florida
  • +1 more
Jan 3, 2023

Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer Trial in Stanford (Alpelisib, Tamoxifen, Infigratinib)

Not yet recruiting
  • Breast Cancer
  • +2 more
  • Stanford, California
    Stanford University
Nov 16, 2022

Breast Cancer Trial in Guangzhou (Everolimus, Letrozole, Fluorouracil)

Completed
  • Breast Cancer
  • Guangzhou, Guangdong, China
    Sun-Yat-Sen Memorial Hospital of Sun-Yat-Sen University
Sep 22, 2021

ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Cancer Trial in Madison, Milwaukee (Onapristone, Fulvestrant)

Recruiting
  • ER-positive Breast Cancer
  • +2 more
  • Madison, Wisconsin
  • +1 more
Jul 7, 2022

Advanced ER+, HER2-Negative Breast Cancer Trial in Waltham (Elacestrant)

Completed
  • Advanced ER+, HER2-Negative Breast Cancer
  • Waltham, Massachusetts
    Radius Pharmaceuticals, Inc.
Aug 16, 2022

Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer Trial

Not yet recruiting
  • Hormone Receptor-positive Breast Cancer
  • +2 more
  • Nashville, Tennessee
    Sarah Cannon Research Institute
Oct 5, 2022